Your session is about to expire
← Back to Search
Treatment for Huntington's Disease
N/A
Recruiting
Led By Bernhard G Landwehrmeyer, MD, PhD
Research Sponsored by CHDI Foundation, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is enrolling over 20,000 participants with the goal of collecting clinical data and biospecimens in order to develop tools for progression and prognosis of Huntington's disease, as well as establish endpoints for interventional studies.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cognitive Assessments: Symbol Digit Modality Test; Stroop Color Naming; Stroop Word Reading; Categorical Verbal Fluency
Functional Assessments: UHDRS '99 Total Functional Capacity, UHDRS '99 Functional Assessment Scale, UHDRS '99 Independence Scale
Motor Assessments: Unified Huntington's Disease Rating Scale (UHDRS) 99 Motor, UHDRS '99 Diagnostic Confidence Level
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
CHDI Foundation, Inc.Lead Sponsor
16 Previous Clinical Trials
4,024 Total Patients Enrolled
Bernhard G Landwehrmeyer, MD, PhDPrincipal InvestigatorUniversity of Ulm
1 Previous Clinical Trials
55 Total Patients Enrolled
Jamie LeveyStudy DirectorCHDI Foundation, Inc.
Share this study with friends
Copy Link
Messenger